Ailux Teams with Lilly to Accelerate AI Antibody Development
PositiveArtificial Intelligence
Ailux, a subsidiary of XtalPi, has partnered with Eli Lilly to enhance the development of bispecific antibodies using AI technology. This collaboration is significant as it aims to expedite the discovery process for treatments targeting various diseases, potentially leading to faster and more effective therapies for patients.
— via World Pulse Now AI Editorial System

